Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

La description de l'entreprise est affichée en anglais.

Visiter le site →

Statistiques Clés

Capitalisation: $2.79M
Ratio P/E: N/A
Plus Haut 52 Sem.: $5.60
Plus Bas 52 Sem.: $0.72
Volume Moyen: 332.81K
Bêta: 1.87

Données fournies par Yahoo Finance via yfinance. Mis à jour quotidiennement.

Info Entreprise

Industrie: Biotechnologie
Bourse: NASDAQ
Pays: United States
Employés: 52